Announcements Trials
Browse Landscape

Phase

Phase NA 22Phase EARLY_PHASE1 1Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 39Glioblastoma 37Glioma 33Prostatic Neoplasms 32Neoplasms 28Multiple Myeloma 26Pancreatic Neoplasms 25Brain Neoplasms 23Colorectal Neoplasms 19Recurrence 18Squamous Cell Carcinoma of Head and Neck 16Melanoma 15Lung Neoplasms 15Neoplasm Metastasis 14Lymphoma, B-Cell 13Lymphoma 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Sarcoma 12Leukemia, Myeloid, Acute 12Hematologic Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumors 10Stomach Neoplasms 9Ovarian Neoplasms 9Skin Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neuroblastoma 8Lymphoma, Non-Hodgkin 8Colonic Neoplasms 8

Interventions

CIMAvax EGF 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pulmonary Disease, Chronic Obstructive × 1 year × Clear all
NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡